Go Pro
→ Rickards Predicts: Trump to buy tiny $2 stock? (From Paradigm Press) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indivior PLC stock logo
INDV
Indivior
$34.94
+0.3%		$38.90
$22.22
▼
$42.81
$4.12B0.822.20 million shs1.02 million shs
Medifast Inc stock logo
MED
Medifast
$12.63
+0.7%		$11.14
$9.22
▼
$14.67
$141.15M0.71225,535 shs54,712 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indivior PLC stock logo
INDV
Indivior
-0.63%-1.33%-4.58%-7.42%+41.18%
Medifast Inc stock logo
MED
Medifast
-1.20%+2.94%-4.63%+3.60%-10.35%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Indivior PLC stock logo
INDV
Indivior
$34.94
+0.3%		$38.90
$22.22
▼
$42.81
$4.12B0.822.20 million shs1.02 million shs
Medifast Inc stock logo
MED
Medifast
$12.63
+0.7%		$11.14
$9.22
▼
$14.67
$141.15M0.71225,535 shs54,712 shs
The 7 Hottest IPO Stories of 2026 Cover
The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Indivior PLC stock logo
INDV
Indivior
-0.63%-1.33%-4.58%-7.42%+41.18%
Medifast Inc stock logo
MED
Medifast
-1.20%+2.94%-4.63%+3.60%-10.35%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Indivior PLC stock logo
INDV
Indivior
2.71
Moderate Buy$45.1729.27% Upside
Medifast Inc stock logo
MED
Medifast
1.67
Reduce$12.00-4.95% Downside

Current Analyst Ratings Breakdown

Latest CSRT, IDH, MED, and INDV Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/21/2026
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeBuy (B-) ➝ Hold (C+)
8/17/2026
Medifast Inc stock logo
MED
Medifast
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D)
8/11/2026
Medifast Inc stock logo
MED
Medifast
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
8/7/2026
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C+) ➝ Buy (B-)
8/5/2026
Indivior PLC stock logo
INDV
Indivior
Barclays PLC logo
Barclays
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Lower Price TargetOverweight$46.00 ➝ $43.00
8/4/2026
Indivior PLC stock logo
INDV
Indivior
Craig Hallum logo
Craig Hallum
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$53.00
8/3/2026
Medifast Inc stock logo
MED
Medifast
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/24/2026
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C) ➝ Hold (C+)
7/13/2026
Medifast Inc stock logo
MED
Medifast
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
7/9/2026
Indivior PLC stock logo
INDV
Indivior
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
6/29/2026
Indivior PLC stock logo
INDV
Indivior
Zacks Research logo
Zacks Research
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Indivior PLC stock logo
INDV
Indivior
$1.24B3.33$2.71 per share12.89($1.76) per share-19.85
Medifast Inc stock logo
MED
Medifast
$385.79M0.37$0.41 per share30.53$17.56 per share0.72
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Indivior PLC stock logo
INDV
Indivior
$210M$2.7912.529.12N/A26.65%-283.11%36.85%10/29/2026 (Estimated)
Medifast Inc stock logo
MED
Medifast
-$18.67M-$2.33N/AN/AN/A-8.08%-6.69%-5.25%11/9/2026 (Estimated)

Latest CSRT, IDH, MED, and INDV Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/3/2026Q2 2026 & Merger
Indivior PLC stock logo
INDV
Indivior
$0.8690$1.15+$0.2810$4.90$306.23 million$343.00 million
8/3/2026Q2 2026
Medifast Inc stock logo
MED
Medifast
-$0.65-$0.28+$0.37-$0.28$72.70 million$76.38 million
6/30/2026Q2 2026
Indivior PLC stock logo
INDV
Indivior
N/A$5.75N/A$4.90N/A$343.00 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Indivior PLC stock logo
INDV
Indivior
N/AN/AN/AN/AN/A
Medifast Inc stock logo
MED
Medifast
N/AN/A-100.00%N/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Indivior PLC stock logo
INDV
Indivior
N/A
0.84
0.66
Medifast Inc stock logo
MED
Medifast
N/A
4.86
4.35

Institutional Ownership

CompanyInstitutional Ownership
Indivior PLC stock logo
INDV
Indivior
60.33%
Medifast Inc stock logo
MED
Medifast
95.51%

Insider Ownership

CompanyInsider Ownership
Indivior PLC stock logo
INDV
Indivior
0.74%
Medifast Inc stock logo
MED
Medifast
3.70%
CompanyEmployeesShares OutstandingFree FloatOptionable
Indivior PLC stock logo
INDV
Indivior
1,051118.01 million117.14 millionNot Optionable
Medifast Inc stock logo
MED
Medifast
87011.18 million10.77 millionOptionable

Recent News About These Companies

Medifast's 3.0 Strategy Takes Shape: Can It Restore Profitable Growth?
September 4 at 11:53 AM  |  zacks.comhttps://www.zacks.com/stock/news/2985149/medifast-s-3-0-strategy-takes-shape-can-it-restore-profitable-growth?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2985149
Why Is Medifast (MED) Down 7.6% Since Last Earnings Report?
September 2 at 12:31 PM  |  zacks.comhttps://www.zacks.com/stock/news/2983875/why-is-medifast-med-down-7-6-since-last-earnings-report?cid=cs-stocknewsapi-ft-realtime_blog-2983875
Ocius Technology to Add Sonar Systems to Bluebottle Fleet: NYSE Content Update
September 2 at 8:55 AM  |  prnewswire.comhttps://www.prnewswire.com/news-releases/ocius-technology-to-add-sonar-systems-to-bluebottle-fleet-nyse-content-update-302867712.html
Medifast (NYSE:MED) Director Parsa Kiai Buys 43,150 Shares
August 29, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-med-insider-buying-and-selling-2026-08-29/
Medifast Insider Makes Bold Move With Major Share Purchase
August 28, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/medifast-insider-makes-bold-move-with-major-share-purchase-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
Medifast (NYSE:MED) Director Purchases 43,150 Shares
August 28, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-medifast-nyse-med-director-purchases-43150-shares-2026-08-28/
Zacks Research Brokers Boost Earnings Estimates for Medifast
August 28, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=30987149
Medifast annonce le lancement du Medifast Metabolic Health Institute
August 27, 2026  |  zonebourse.comZ
Medifast® Announces the Launch of the Medifast Metabolic Health Institute™
August 27, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260827920523/en/Medifast%C2%AE-Announces-the-Launch-of-the-Medifast-Metabolic-Health-Institute%E2%84%A2/
Medifast (NYSE:MED) Director Parsa Kiai Buys 4,329 Shares of Stock
August 27, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-med-insider-buying-and-selling-2026-08-27/
Can Medifast Capitalize on Rising GLP-1 Use With Metabolic Health?
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980585/can-medifast-capitalize-on-rising-glp-1-use-with-metabolic-health?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2980585
Parsa Kiai Buys 4,329 Shares of Medifast (NYSE:MED) Stock
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-parsa-kiai-buys-4329-shares-of-medifast-nyse-med-stock-2026-08-26/
All You Need to Know About Medifast (MED) Rating Upgrade to Buy
August 26, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2980489/all-you-need-to-know-about-medifast-med-rating-upgrade-to-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_12_zacks_rank_upgrade-2980489
Equities Analysts Set Expectations for Medifast Q3 Earnings
August 26, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-equities-analysts-set-expectations-for-medifast-q3-earnings-2026-08-26/
Insider Buying: Medifast (NYSE:MED) Director Buys $342,069.42 in Stock
August 22, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nyse-med-insider-buying-and-selling-2026-08-22/
Insider Makes Bold Move With Fresh Medifast Share Grab
August 21, 2026  |  tipranks.comhttps://www.tipranks.com/news/insider-trading/insider-makes-bold-move-with-fresh-medifast-share-grab-insider-trading-news?utm_source=marketbeat.com&utm_medium=referral
3 reasons to sell MED and 1 stock to buy instead
August 21, 2026  |  msn.comhttps://www.msn.com/en-us/money/top-stocks/3-reasons-to-sell-med-and-1-stock-to-buy-instead/ar-AA2aDVLi
Insider Buying: Medifast (NYSE:MED) Director Acquires 29,337 Shares of Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/insider-buying-medifast-nysemed-director-acquires-29337-shares-of-stock-2026-08-21/
Medifast (NYSE:MED) Director Purchases 43,150 Shares of Stock
August 21, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/medifast-nysemed-director-purchases-43150-shares-of-stock-2026-08-21/
Can Medifast's New Compensation Plan Accelerate Coach Growth?
August 21, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2978443/can-medifast-s-new-compensation-plan-accelerate-coach-growth?cid=cs-stocknewsapi-ft-analyst_blog|rank_focused-2978443
Medifast (NYSE:MED) Cut to Hold at Zacks Research
August 13, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/medifast-nysemed-cut-to-hold-at-zacks-research-2026-08-13/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Moderna logo displayed in a laboratory setting with a vaccine vial, petri dishes, and a microscope.
Moderna’s 177% Surge Has Investors Asking What Comes Next
By Sam Quirke | August 21, 2026
Illustration of a vial with an upward stock price chart and DNA double helix against a city skyline, symbolizing biotech growth.
2 Biotech Stocks Shaping Up for Major Breakouts
By Ryan Hasson | August 22, 2026
Interior of a Dick's Sporting Goods store showing shelves of basketballs, gloves, and a wall of shoes.
Can DICK'S Turn Foot Locker Into a Winner?
By Peter Frank | August 9, 2026
Amazon delivery worker in branded vest holding a Prime package at a customer's front door.
A Star Investor Just Trimmed Amazon—Here's What It means
By Sam Quirke | August 18, 2026
AST SpaceMobile logo with satellite in orbit beaming signals down to an illuminated Earth at night.
AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
By Jessica Mitacek | August 11, 2026
Indivior stock logo

Indivior NASDAQ:INDV

$34.94 +0.11 (+0.32%)
As of 04:00 PM Eastern

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.

Medifast stock logo

Medifast NYSE:MED

$12.62 +0.09 (+0.68%)
As of 03:57 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Medifast, Inc., through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names. The company markets its products through point-of-sale transactions, as well as through ecommerce platform. Medifast, Inc. was founded in 1980 and is headquartered in Baltimore, Maryland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas